The Resorbable Magnesium Scaffold Magmaris in Acute Coronary Syndrome: An Appraisal of Evidence and User Group Guidance.
Acute coronary syndrome
Clinical outcomes
Magmaris
Journal
Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
22
06
2021
revised:
30
08
2021
accepted:
27
09
2021
pubmed:
12
10
2021
medline:
25
5
2022
entrez:
11
10
2021
Statut:
ppublish
Résumé
Bioresorbable scaffolds provide transient vessel support without the long-term limitations of permanent metallic drug-eluting stents. The sirolimus-eluting resorbable magnesium scaffold Magmaris is the only CE-marked metallic bioresorbable scaffold and provides short-term lumen support before being completely bioresorbed. To date, clinical trial results have demonstrated low adverse event rates in patients with simple coronary lesions. Seven European centers with large experience in Magmaris implantation, combined efforts in an informal collaboration to evaluate and appraise clinical data currently available regarding the performance of Magmaris in patients presenting with acute coronary syndromes, and to supply user-advice on patient selection and optimal implantation practice.
Identifiants
pubmed: 34629285
pii: S1553-8389(21)00674-6
doi: 10.1016/j.carrev.2021.09.012
pii:
doi:
Substances chimiques
Magnesium
I38ZP9992A
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
106-113Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.